Clinical Trials | December 30, 2025
Senhwa Biosciences launches groundbreaking trial for HER2-positive tumours
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Submission to be reviewed under FDA real-time oncology review and Project Orbis
In a rare occurrence worldwide, the CK Birla Hospital® treats 32-year-old woman for a giant mesenteric tumour via complex laparoscopic surgery
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
Over 8.8?million Indians aged 60 and above currently live with dementia,
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
Subscribe To Our Newsletter & Stay Updated
